Complement in Typical Hemolytic Uremic Syndrome

 

 Buy Article Permissions and Reprints

ABSTRACT

Hemolytic uremic syndrome (HUS) is a severe disease characterized by the clinical triad of hemolytic anemia, thrombocytopenia, and acute renal failure. HUS exists in two forms: the atypical diarrhea-negative HUS, which is often associated with complement disorders, and the more frequent diarrheal-associated typical HUS, which is caused by infections with enterohemorrhagic Escherichia coli. The virulence factors of the latter have been studied well, and Shiga toxin (Stx)2 is reported to represent the most important one. In contrast, risk factors on the host side have not been intensively studied until recently: Complement activation products have been detected in the serum and plasma of HUS patients, and an in vitro study could show that Stx2 not only damages the kidney directly but also indirectly via complement, in two ways. First, it activates complement, and second, it delays the functions of its control protein factor H on the cell surface, both known to damage the kidney.

REFERENCES

• 1 Karch H, Tarr P I, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine.  Int J Med Microbiol. 2005;  295(6–7) 405-418
  CrossrefPubMedGoogle Scholar
• 2 Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes.  Annu Rev Med. 2008;  59 293-309
  CrossrefPubMedGoogle Scholar
• 3 Orth D, Grif K, Khan A B, Naim A, Dierich M P, Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.  Diagn Microbiol Infect Dis. 2007;  59(3) 235-242
  CrossrefPubMedGoogle Scholar
• 4 te Loo D M, Monnens L A, van Der Velden T J et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome.  Blood. 2000;  95(11) 3396-3402
  PubMedGoogle Scholar
• 5 Orth D, Grif K, Zimmerhackl L B, Würzner R. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans.  Expert Rev Anti Infect Ther. 2008;  6(1) 101-108
  CrossrefPubMedGoogle Scholar
• 6 Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children.  Pediatr Nephrol. 2008;  23(11) 1957-1972
  CrossrefPubMedGoogle Scholar
• 7 Caprioli J, Remuzzi G. Complement hyperactivation may cause atypical haemolytic uraemic syndrome—gain-of-function mutations in factor B.  Nephrol Dial Transplant. 2007;  22(9) 2452-2454
  CrossrefPubMedGoogle Scholar
• 8 Frémeaux-Bacchi V, Miller E C, Liszewski M K et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.  Blood. 2008;  112(13) 4948-4952
  CrossrefPubMedGoogle Scholar
• 9 Speth C, Würzner R, Stoiber H, Dierich M P. Complement. In: Paul WE Fundamental Immunology. Philadelphia, PA; Lippincott-Raven 2008: 1047-1078
  PubMedGoogle Scholar
• 10 Würzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry.  Mol Immunol. 1999 36(4–5) 249-260
  PubMedGoogle Scholar
• 11 Orth D, Khan A B, Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.  J Immunol. 2009;  182(10) 6394-6400
  CrossrefPubMedGoogle Scholar
• 12 Monnens L, Molenaar J, Lambert P H, Proesmans W, van Munster P. The complement system in hemolytic-uremic syndrome in childhood.  Clin Nephrol. 1980;  13(4) 168-171
  PubMedGoogle Scholar
• 13 Thurman J M, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome.  Clin J Am Soc Nephrol. 2009;  4(12) 1920-1924
  CrossrefPubMedGoogle Scholar
• 14 Markiewski M M, Lambris J D. The role of complement in inflammatory diseases from behind the scenes into the spotlight.  Am J Pathol. 2007;  171(3) 715-727
  CrossrefPubMedGoogle Scholar
• 15 van Setten P A, van Hinsbergh V W, van den Heuvel L P et al. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome.  Pediatr Res. 1998;  43(6) 759-767
  CrossrefPubMedGoogle Scholar
• 16 Lathem W W, Grys T E, Witowski S E et al. StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor.  Mol Microbiol. 2002;  45(2) 277-288
  CrossrefPubMedGoogle Scholar
• 17 Grys T E, Walters L L, Welch R A. Characterization of the StcE protease activity of Escherichia coli O157:H7.  J Bacteriol. 2006;  188(13) 4646-4653
  CrossrefPubMedGoogle Scholar
• 18 Lathem W W, Bergsbaken T, Welch R A. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7.  J Exp Med. 2004;  199(8) 1077-1087
  CrossrefPubMedGoogle Scholar
• 19 Giannakis E, Jokiranta T S, Male D A et al. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein.  Eur J Immunol. 2003;  33(4) 962-969
  CrossrefPubMedGoogle Scholar
• 20 Sánchez-Corral P, Pérez-Caballero D, Huarte O et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.  Am J Hum Genet. 2002;  71(6) 1285-1295
  CrossrefPubMedGoogle Scholar
• 21 Martinez-Barricarte R, Pianetti G, Gautard R European Working Party on the Genetics of HUS et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2008;  19(3) 639-646
  CrossrefPubMedGoogle Scholar
• 22 Paixão-Cavalcante D, Botto M, Cook H T, Pickering M C. Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.  Clin Exp Immunol. 2009;  155(2) 339-347
  CrossrefPubMedGoogle Scholar
• 23 Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells.  Thromb Haemost. 1997;  77(2) 394-398
  PubMedGoogle Scholar
• 24 Wojta J, Huber K, Valent P. New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype.  Pathophysiol Haemost Thromb. 2003;  33(5-6) 438-441
  CrossrefPubMedGoogle Scholar

Reinhard WürznerM.D. Ph.D. 

Division of Hygiene and Medical Microbiology, Innsbruck Medical University

Fritz-Pregl. Str. 3, A-6020 Innsbruck, Austria

Email: reinhard.wuerzner@i-med.ac.at